8-K filing — Boundless Bio, Inc. (BOLD)
Filed: 2026-08-28 AccNo: 0001193125-26-374787 Size: 320 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Callio Therapeutics Appoints Zachary Hornby As CEO
Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancerPiers Ingram, PhD, Co-Founder, transitions to Senior Advisor and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.61) by 73.77 percent. This is a 51.43 percent decrease over losses of $(0.70) per share from
Crude Oil Down Over 1%; US Manufacturing PMI Surges In June
US stocks lower, Nasdaq falls 500 points. Dow down 0.04%, Nasdaq 1.91%, S&P 500 1.27%. Consumer staples up 1.4%, tech down 2.3%. S&P PMI rises.